Breaking News, Collaborations & Alliances

Cambrex Partners with Lilly to Support Biotech Innovation

Will deliver accelerated access to clinical development capabilities for Lilly's biotech collaborators.

Author Image

By: Charlie Sternberg

Associate Editor

Cambrex, a global contract development and manufacturing organization (CDMO), has signed an agreement with Eli Lilly and Company (Lilly) to deliver accelerated access to clinical development capabilities for Lilly’s biotech collaborators.   Through this agreement, Cambrex will partner with Lilly Catalyze360-ExploR&D, Lilly’s early external innovation and collaboration arm, to provide drug substance, drug product, analytical service labs and R&D expertise to Lilly Catalyze36...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters